LAKEWOOD, Colo., USA—5 January 2015—As part of its continued focus on innovation and blood safety, Terumo BCT welcomes Colonel (Ret.) Richard Gonzales to the company as the director of Grant Management and Government Sponsored Research. Colonel (Ret.) Gonzales has more than 25 years of experience in blood banking and transfusion medicine through his work with the United States (U.S.) Army.
Under the leadership of Colonel (Ret.) Gonzales, the Terumo BCT grant management team will pursue additional grants and appropriations. This focus supports Terumo BCT's commitment to innovation and work in areas like: therapeutics, whole blood collections, automated collections and regenerative medicine programs.
- Terumo BCT has received more than $25 million in appropriations, grants and contracts since 2004
- Grants and government sponsored research have contributed to important innovations from Terumo BCT, such as developing certain aspects of the Mirasol® Pathogen Reduction Technology System for whole blood and certain clinical studies conducted in the U.S. and Europe
- Colonel (Ret.) Gonzales and his team will work to identify and manage granting opportunities that are in line with Terumo BCT's strategic objectives
Colonel (Ret.) Richard Gonzales, Director of Grant Management & Government Sponsored Research, Terumo BCT
"I'm excited to join Terumo BCT and help expand our footprint with grants and government sponsored research. After many years of service in the U.S. Army, I can affirm that there are great synergies for new innovations by Terumo BCT if we continue our work with the U.S. government and other non-government organizations (NGOs). There are mutual benefits in meeting capability gaps in blood safety, not only in the U.S., but worldwide."
Ray Goodrich, PhD, Vice President of Scientific and Clinical Affairs, Terumo BCT
"Our industry is becoming more reliant on collaboration between agencies and companies like Terumo BCT to develop products, solve problems and help patients in new ways. Colonel (Ret.) Gonzales and his team will help keep Terumo BCT at the forefront of industry trends and continue our commitment to innovation."
About Terumo BCT:
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
Global Corporate Communications